David Laber
Overview
Explore the profile of David Laber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scott J, Bowker S, Brocklehurst K, Brown H, Clarke D, Easter A, et al.
J Med Chem
. 2014 Oct;
57(21):8984-98.
PMID: 25286150
Agonism of GPR119 is viewed as a potential therapeutic approach for the treatment of type II diabetes and other elements of metabolic syndrome. During progression of a previously disclosed candidate...
2.
Scott J, Brocklehurst K, Brown H, Clarke D, Coe H, Groombridge S, et al.
Bioorg Med Chem Lett
. 2013 May;
23(11):3175-9.
PMID: 23628336
A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of...
3.
Scott J, Birch A, Brocklehurst K, Broo A, Brown H, Butlin R, et al.
J Med Chem
. 2012 May;
55(11):5361-79.
PMID: 22545772
G protein coupled receptor 119 (GPR119) is viewed as an attractive target for the treatment of type 2 diabetes and other elements of the metabolic syndrome. During a program toward...
4.
Morgan S, Sherlock M, Gathercole L, Lavery G, Lenaghan C, Bujalska I, et al.
Diabetes
. 2009 Aug;
58(11):2506-15.
PMID: 19675138
Objective: Glucocorticoid excess is characterized by increased adiposity, skeletal myopathy, and insulin resistance, but the precise molecular mechanisms are unknown. Within skeletal muscle, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) converts cortisone...
5.
Krige D, Needham L, Bawden L, Flores N, Farmer H, Miles L, et al.
Cancer Res
. 2008 Aug;
68(16):6669-79.
PMID: 18701491
CHR-2797 is a novel metalloenzyme inhibitor that is converted into a pharmacologically active acid product (CHR-79888) inside cells. CHR-79888 is a potent inhibitor of a number of intracellular aminopeptidases, including...